Skip to content
Blerp – Lifestyle
Author:
CG Oncology Inc.
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
November 16, 2026
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
November 6, 2026
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
October 13, 2026
CG Oncology to Present at Upcoming Investor Conferences in September
September 2, 2026
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
July 27, 2026
CG Oncology to Present at Upcoming Investor Conferences in June
May 28, 2026
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
May 19, 2026